Dihydrodiol ibrutinib

CAS : 1654820-87-7

Ref. 3D-ERC82087

Informations sur le produit

• Nom: Dihydrodiol ibrutinib

Description

Dihydrodiol ibrutinib is a tyrosine kinase inhibitor drug that has been shown to inhibit the growth of cancer cells by targeting the epidermal growth factor receptor. It can be used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Dihydrodiol ibrutinib inhibits wild-type mouse cyp3a4 and human cyp3a4, which are responsible for metabolizing this drug. This inhibition leads to an increase in the blood concentration of dihydrodiol ibrutinib, which is currently being studied as a potential treatment for autoimmune diseases. The IR spectroscopy studies show that dihydrodiol ibrutinib binds to tubule cells in the kidney, which may lead to renal toxicity. The FTIR spectroscopy also showed that this drug binds with trifluoroacetic acid (TFA) during sample preparation, which may affect its stability.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 474.5 g/mol
• Formule: C₂₅H₂₆N₆O₄
• Degré de pureté: Min. 95%